53833 Long-term Safety and Efficacy of Risankizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: Interim Analysis of Results From the LIMMitless Open-label Extension Trial For up to 6 Years of Follow-up - 02/09/24
Doi : 10.1016/j.jaad.2024.07.246
Kim A. Papp, MD, PhD
Alliance Clinical Trials and Probity Medical Research, Waterloo, Ontario, Canada, and Division of Dermatology, University of Toronto, Toronto, Ontario, Canada
Mark G. Lebwohl, MD
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, United States
Lluís Puig, MD, PhD
Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Stefan Beissert, MD
Department of Dermatology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany
Le texte complet de cet article est disponible en PDF.
| Commercial Support: AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the abstract. All authors had access to relevant data and participated in the drafting, review, and appr. |
© 2024
Vol 91 - N° 3S
P. AB60 - septembre 2024 Retour au numéro
Article précédent
- 50668 Long-term Impact of Apremilast on Cardiometabolic Parameters and the Relationship of Cardiometabolic Changes With Psoriasis Efficacy
- Bruce Strober, Jeffrey Crowley, Richard Langley, Cynthia Deignan, Lichen Teng, Zhenwei Zhou, Nehal Mehta
- 52620 Long-term safety and efficacy of secukinumab over 236 weeks in children and adolescents with severe chronic plaque psoriasis: Results of a double-blind, randomized controlled phase III trial
- Shoba Ravichandran, Andrzej Kaszuba, Dorota Krasowska, Nina Magnolo, Amita Bansal, Swapnil S. Dahale, Ruvie Martin, Bertrand Paguet, Philemon Papanastasiou, Kulli Kingo
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?